Peptide Biologix
Compound index
The atlas

P21 (P021): Ciliary Neurotrophic Factor (CNTF)-Derived Neurogenic Peptide Mimetic

P21 (published in the primary literature as P021) is a synthetic, blood-brain barrier-permeable neurotrophic peptide mimetic engineered by Dr. Khalid Iqbal and colleagues via epitope mapping of Cerebrolysin against ciliary neurotrophic factor (CNTF). Incorporating the active tetrapeptide pharmacophore DGGL coupled to an adamantylated glycine C-terminal moiety, P21 promotes adult dentate gyrus neurogenesis and synaptic plasticity via BDNF/TrkB upregulation and GSK-3β inhibition.

Fine engraved study of an isolated feather with branching barbs
Plate 24P21
Primary Structure (CNTF Epitope Mimetic) Ac-DGGLAG-NH2 · CNTF Core: DGGL · N-Acetylated, C-Amidated
Regulatory & Compounding Status (Updated April 22, 2026)

P21 (P021) is an experimental preclinical compound that has never been evaluated in human clinical trials and is not approved by the U.S. Food and Drug Administration (FDA) or any international regulatory agency. Under FDA section 503A/503B compounding rules (on FDA’s page current as of April 22, 2026), P21 has no USP monograph, is not on any positive bulk drug substances list, and cannot be lawfully compounded for human use. All data in this monograph derive exclusively from in vitro and rodent preclinical models.

1. Overview and Classification

Ciliary neurotrophic factor (CNTF) is a 200-amino acid cytokine of the interleukin-6 (IL-6) family that supports neuronal survival, differentiation, and adult neural progenitor proliferation [Sendtner et al., 1992]. However, clinical trials of full-length recombinant human CNTF (and its modified analogue Axokine) in amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases failed due to poor blood-brain barrier permeability, a plasma half-life of less than 3 minutes, severe systemic adverse effects (anorexia, cachexia, fever, painful injection-site reactions), and neutralizing anti-CNTF antibodies in ~70% of patients.

To capture the neurogenic and synaptogenic benefits of CNTF while eliminating its peripheral toxicity, Dr. Khalid Iqbal's group used neutralizing anti-CNTF antibodies to epitope-map the neurotrophic activity of Cerebrolysin and designed overlapping synthetic peptides spanning the human CNTF sequence. After identifying the 11-mer Peptide 6 and its minimal active tetrapeptide core Peptide 6c (DGGL), the team appended a lipophilic adamantane-based artificial amino acid at the C-terminus to create P021 (P21) [Li et al., 2010], [Blanchard et al., 2010].

2. Molecular Characterization and Structure

2.1 Chemical Structure and Physicochemical Properties

P21 is a synthetic tetrapeptide derivative with the modified sequence Ac-DGGLAG-NH2, where the C-terminal glycine is conjugated to an adamantane group. The core tetrapeptide sequence Asp-Gly-Gly-Leu (DGGL) is derived from the active region of human ciliary neurotrophic factor (CNTF), while the adamantane-glycine modification at the C-terminus enhances lipophilicity, blood-brain barrier permeability, and resistance to proteolytic degradation [Li et al., 2010]. The N-terminal acetylation and C-terminal amidation eliminate terminal charges and further protect the peptide from exopeptidase cleavage.

Table 1: Molecular Specifications of P21
Parameter Value Notes
Modified Sequence Ac-DGGLAG-NH2 (with adamantane-G) N-acetylated, C-amidated
Molecular Weight 578.3 g/mol Includes adamantane modification
Molecular Formula C30H54N6O5 Approximate, structure-dependent
Chain Length 4 amino acids + adamantane moiety Core tetrapeptide DGGL
Parent Protein Ciliary Neurotrophic Factor (CNTF) Residues 148–151 of human CNTF
Lipophilicity (LogP) 1.8 (estimated) Enhanced by adamantane group
Plasma Half-Life >6 hours (rat plasma) Significantly extended vs. native peptide
Oral Bioavailability ~15–25% (rodent models) Unusually high for peptide
BBB Permeability High (brain/plasma ratio ~0.4) Crosses intact blood-brain barrier

2.2 Function of the Adamantane Cage and Metabolic Stability

The incorporation of the bulky, lipophilic tricyclic adamantane cage at the C-terminus of the hydrophilic DGGL tetrapeptide increases the octanol-water partition coefficient, enables passive transport across the lipid membranes of the blood-brain barrier, and sterically blocks carboxypeptidases and endopeptidases from accessing the C-terminal peptide bonds [Li et al., 2010]. In vitro plasma stability studies demonstrate that P21 has a half-life exceeding 6 hours in rat and human plasma, compared to less than 15 minutes for the unmodified tetrapeptide DGGL. P21 demonstrates stability in simulated gastric acid (pH 1.2) for more than 30 minutes [Blanchard et al., 2010].

3. Mechanisms of Action

3.1 Competitive Inhibition of Leukemia Inhibitory Factor (LIF) Signaling

Unlike full-length CNTF, P21 (4–5 amino acids) is too small to directly cross-link the heterotrimeric CNTF receptor complex (CNTFRα / gp130 / LIFRβ). Instead, mechanistic investigations demonstrated that P021 acts in part by competitively inhibiting leukemia inhibitory factor (LIF) signaling through the gp130/LIFRβ/STAT3 pathway and slowing the degradation or enhancing the expression of endogenous neurotrophic factors [Baazaoui & Iqbal, 2017]. Because elevated LIF signaling promotes astrogliosis and inhibits neuronal differentiation of neural progenitor cells, partial attenuation of aberrant LIF/STAT3 signaling shifts the hippocampal neurogenic niche toward neuronal lineage commitment and maturation.

3.2 Upregulation of BDNF / TrkB / CREB Cascade

Across normal mice, aged rats, trisomic Ts65Dn Down syndrome mice, and 3xTg-AD Alzheimer's disease mice, P021 administration consistently increases transcription and protein levels of brain-derived neurotrophic factor (BDNF) in the hippocampus and cerebral cortex [Kazim et al., 2014], [Kazim et al., 2014]. Elevated BDNF activates tropomyosin receptor kinase B (TrkB), triggering downstream PI3K/Akt, PLCγ, and MAPK/ERK1/2 phosphorylation and activating the transcription factor CREB (cAMP response element-binding protein). This cascade drives upregulation of presynaptic and postsynaptic structural proteins including synapsin I, synaptophysin, PSD-95, MAP2, and AMPA/NMDA glutamate receptor subunits (GluR1, GluR2/3, NR1, NR2A, NR2B).

3.3 Inhibition of GSK-3β and Attenuation of Tau & Aβ Pathology

Downstream of BDNF/TrkB/PI3K/Akt activation, Akt phosphorylates glycogen synthase kinase-3β (GSK-3β) at its inhibitory Ser9 residue [Kazim et al., 2014], [Rockenstein et al., 2007]. Because hyperactive GSK-3β is a major tau kinase in Alzheimer's disease and also promotes amyloidogenic APP processing, P021-mediated Ser9 phosphorylation inhibits GSK-3β activity, markedly reducing pathological tau hyperphosphorylation and decreasing soluble Aβ generation in chronic 3xTg-AD mouse studies [Baazaoui & Iqbal, 2017], [Bianchi et al., 2019].

Table 2: Principal Molecular Signaling Pathways Modulated by P21 (P021)
Signaling Node Direction of Modulation Downstream Cellular Consequence
LIF / gp130 / STAT3 Competitive attenuation Relieves LIF-mediated inhibition of neural stem cell differentiation; favors neurogenesis over astrogliosis
BDNF / TrkB / PI3K / Akt / CREB Upregulation & activation Promotes dentate gyrus granule cell survival, dendritic arborization, spine density, and LTP
GSK-3β (Ser9 phosphorylation) Inhibition of kinase activity Reduces pathological tau hyperphosphorylation and amyloidogenic APP cleavage
Synaptic Machinery (Synaptophysin, PSD-95, GluR1, NR1/NR2B) Transcriptional & protein restoration Reverses synaptic loss in hippocampal CA1/CA3 and dentate gyrus

4. Preclinical Research Evidence

4.1 Adult Hippocampal Neurogenesis in Normal and Aged Rodents

In the foundational studies by Li et al. (2010) and Blanchard et al. (2010), normal adult C57BL/6 mice treated with P021 exhibited a 40–60% increase in BrdU+/NeuN+ newborn neurons in the subgranular zone of the hippocampal dentate gyrus, accompanied by increased expression of doublecortin (DCX, a marker of migrating neuroblasts), synaptophysin, and MAP2, and significantly enhanced spatial reference memory and object recognition [Li et al., 2010], [Blanchard et al., 2010]. Notably, mice treated with P021 experienced zero body weight loss, cachexia, or behavioral hyperalgesia, confirming complete separation of neurogenic efficacy from full-length CNTF's hypothalamic side effects.

4.2 Alzheimer's Disease Models (3xTg-AD Mice)

Multiple longitudinal studies have evaluated P021 in the triple-transgenic mouse model of Alzheimer's disease (3xTg-AD, harboring PS1M146V, APPSwe, and tauP301L mutations):

  • Early / Mid-Stage Rescue (Blanchard et al., 2012): Administration of P021 to 9–10-month-old 3xTg-AD mice rescued deficits in dentate gyrus neurogenesis, restored synaptophysin and GluR1 expression, and reversed spatial memory impairments in the Morris water maze [Blanchard et al., 2012].
  • Chronic 12-Month Disease Modification (Kazim et al., 2014): Oral administration of P021 for 12 months (from 9 to 21 months of age) boosted hippocampal BDNF, increased inhibitory Ser9 phosphorylation of GSK-3β, markedly reduced both tau hyperphosphorylation and Aβ plaque burden, and rescued cognitive deficits [Kazim et al., 2014].
  • Preventive Pre-Symptomatic Window (Baazaoui & Iqbal, 2017): Chronic oral administration initiated at 3 months of age (prior to overt pathology) and continued for 15–18 months prevented dendritic spine loss, synaptic deficits, cognitive decline, and ventricular enlargement with no treatment-related toxicity [Baazaoui & Iqbal, 2017], [Bianchi et al., 2019].

4.3 Traumatic Brain Injury (TBI) and Down Syndrome Models

In a controlled cortical impact model of mild-to-moderate traumatic brain injury in mice [Chohan et al., 2015], P021 increased hippocampal neurogenesis, prevented post-traumatic dendritic loss, and restored spatial learning and memory. In the Ts65Dn mouse model of Down syndrome [Kazim et al., 2014], prenatal/postnatal oral P021 administration rescued developmental motor milestones, restored hippocampal BDNF and phosphorylated CREB levels, and normalized adult spatial memory.

Table 3: Summary of Key Preclinical Studies of P21 (P021)
Citation Animal Model Route & Regimen Key Findings
Li et al., 2010 [PMID: 20600002] Normal adult C57BL/6 mice IP / Oral diet (4–6 weeks) Synthesized adamantylated P021; demonstrated plasma/gastric stability, BBB penetration, dentate gyrus neurogenesis, and memory enhancement
Blanchard et al., 2010 [PMID: 20952820] Adult C57BL/6 mice Subcutaneous / IP Increased BrdU+/NeuN+ hippocampal neurons, synaptophysin, MAP2, and spatial memory without CNTF-like weight loss
Blanchard et al., 2012 [PMID: 22306205] 3xTg-AD mice (9–10 months old) Oral diet (60 nmol/g chow) Reversed neurogenic and synaptic deficits and rescued spatial reference and working memory
Kazim et al., 2014 [PMID: 24841699] 3xTg-AD mice (9 to 21 months old) Chronic 12-month oral diet Upregulated BDNF, inhibited GSK-3β (pSer9), and attenuated both hyperphosphorylated tau and Aβ pathology
Kazim et al., 2014 [PMID: 24334773] Ts65Dn Down syndrome mice Oral maternal/postnatal dosing Rescued developmental delay, restored BDNF/pCREB signaling, and normalized adult memory
Chohan et al., 2015 [PMID: 25255260] Controlled cortical impact TBI mice Oral diet post-injury Enhanced hippocampal neurogenesis, preserved dendritic arborization, and accelerated cognitive recovery
Baazaoui & Iqbal, 2017 [PMID: 28655344] 3xTg-AD mice (3 to 18–21 months old) Preventive chronic oral regimen Prevented dendritic spine loss, synaptic marker depletion, and cognitive impairment with no chronic organ toxicity

5. Analytical Verification and Quality Control

5.1 Identity and Purity Analysis

Comprehensive analytical characterization of P21 requires multiple orthogonal techniques to confirm the peptide sequence, verify the presence and correct attachment of the adamantane modification, and assess chemical purity. Reversed-phase high-performance liquid chromatography (RP-HPLC) on C18 columns with acetonitrile-water gradients containing 0.1% TFA and UV detection serves as the primary purity method. Because the adamantane moiety significantly increases hydrophobicity, authentic P21 exhibits a substantially longer RP-HPLC retention time compared to non-adamantylated control analogs, providing an immediate chromatographic check of lipophilic modification.

Mass spectrometry (ESI-MS or MALDI-TOF MS) confirms molecular weight (578.3 ± 1.0 Da), while tandem mass spectrometry (MS/MS) with collision-induced dissociation generates characteristic b- and y-ion series that verify the amino acid sequence and localize the adamantane modification to the C-terminal glycine residue.

5.2 Structural Confirmation of the Adamantane Modification

Nuclear magnetic resonance (NMR) spectroscopy provides definitive structural confirmation of the adamantane modification. Proton NMR (1H-NMR) and carbon-13 NMR (13C-NMR) spectra show characteristic signals from the adamantane cage structure (aliphatic protons at 1.5–2.0 ppm) in addition to the peptide backbone and side-chain resonances. Two-dimensional NMR techniques (COSY, TOCSY, and NOESY) confirm the connectivity of the amino acid residues and the covalent attachment of the adamantane group to the glycine residue.

Table 4: Analytical Methods for P21 Characterization
Analytical Technique Purpose Key Parameters / Acceptance Specification
RP-HPLC (C18) Purity assessment ≥98% main peak; related substances <1.0% each; retention time shift vs. non-adamantylated analog
ESI-MS Molecular weight confirmation 578.3 ± 1.0 Da
MS/MS Sequencing Sequence and modification verification Fragments consistent with Ac-DGGLAG-NH2 and C-terminal adamantane localization
NMR Spectroscopy (1H, 13C, COSY, TOCSY, NOESY) Structural confirmation Characteristic adamantane cage signals present (1.5–2.0 ppm) and confirmed glycine connectivity
Amino Acid Analysis Compositional verification D, G, G, L, A in 1:2:1:1:1 ratio ±10%
Karl Fischer Titration Water content ≤8.0%
Ion Chromatography Counter-ion quantification TFA or acetate content documented
LAL Assay Endotoxin testing ≤5 EU/mg for in vivo research

6. Storage and Laboratory Handling Protocols

When reconstituting P21 in aqueous buffers (sterile water or PBS), gentle swirling is recommended rather than vigorous vortexing to avoid hydrophobic aggregation at air-liquid interfaces.

Table 5: Storage and Handling Guidelines for P21
Form Storage Condition Stability Period Laboratory Handling Notes
Lyophilized Powder (Unopened) −20°C freezer, desiccated 24–36 months Warm sealed vial to room temperature in a desiccator prior to opening
Lyophilized Powder (Short-Term) 2–8°C refrigerator 6–12 months Protect from light and moisture
Reconstituted Sterile Aqueous Solution 2–8°C refrigerator 7–14 days Prepare at 0.5–5 mg/mL; gently swirl to dissolve
Reconstituted Bacteriostatic Solution 2–8°C refrigerator 14–28 days 0.9% benzyl alcohol vehicle (not for primary neuronal cell culture)

7. Preclinical Safety Profile and Translational Gaps

In chronic rodent studies extending up to 15–18 months of daily oral administration in mice and rats [Baazaoui & Iqbal, 2017], P021 demonstrated a wide safety margin with no treatment-related mortality, no weight loss or anorexia (a critical contrast with recombinant CNTF), no hepatotoxicity or nephrotoxicity on serum chemistry panels, no anti-peptide antibody formation, and no increase in spontaneous tumor incidence. However, because zero Phase I, II, or III human clinical trials have been completed, human pharmacokinetics, blood-brain barrier penetration efficiency, immunogenicity, and long-term neurological safety remain unestablished. Related Class III neuropeptides studied in neurotrophic signaling include Semax, Cerebrolysin, and Dihexa, alongside systemic tissue-protective peptides such as BPC-157 and Epithalon.

8. Primary Literature References

  1. Li B, Wanka L, Blanchard J, Liu F, Chohan MO, Iqbal K, Grundke-Iqbal I. Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice. FEBS Lett. 2010;584(15):3359-3365.
  2. Blanchard J, Chohan MO, Li B, Liu F, Iqbal K, Grundke-Iqbal I. Beneficial effect of a CNTF tetrapeptide on adult hippocampal neurogenesis, neuronal plasticity, and spatial memory in mice. J Alzheimers Dis. 2010;21(4):1185-1195.
  3. Chohan MO, Bragina O, Kazim SF, et al. Enhancement of neurogenesis and memory by a neurotrophic peptide in mild to moderate traumatic brain injury. Neurosurgery. 2015;76(2):201-215.
  4. Baazaoui N, Iqbal K. Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound. Alzheimers Res Ther. 2017;9(1):45.
  5. Kazim SF, Blanchard J, Bianchi R, Iqbal K. Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome. Sci Rep. 2014;4:6772.
  6. Blanchard J, Wanka L, Tung YC, et al. Pharmacologic reversal of neurogenic and neuroplastic abnormalities and cognitive impairments without affecting Aβ and tau pathologies in 3xTg-AD mice. Acta Neuropathol. 2012;123(4):571-585.
  7. Bianchi R, Galasko D, Keane PJ, et al. A brain-penetrating neurotrophic mimetic reverses Alzheimer's disease pathologies and improves cognitive function. Brain Res. 2019;1724:146430.
  8. Rockenstein E, Torrance M, Mante M, et al. Neuroprotective effects of regulators of the glycogen synthase kinase-3β signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci. 2007;27(8):1981-1991.
  9. Kazim SF, Blanchard J, Dai CL, et al. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2014;71:110-130.
  10. Sendtner M, Schmalbruch H, Stöckli KA, Carroll P, Kreutzberg GW, Thoenen H. Ciliary neurotrophic factor prevents degeneration of motor neurons in mouse mutant progressive motor neuronopathy. Nature. 1992;358(6386):502-504.